samples: A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
Study summary
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
* Planned surgical tumor resection,
* No objection to participate in research
* Signed genetic consent
Exclusion Criteria:
* Patients under guardianship, curatorship or protective supervision
* Taking immunosuppressants
* Pregnant or breast-feeding women
* Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Primary outcome measure(s)
Molecular mechanism — at inclusion (T0) Description of the molecular mechanism involved in the progression and recurrence of glioblastoma
Metabolic mechanism — at inclusion (T0) Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.
Immune mechanism — at inclusion (T0) Description of the immune mechanism involved in the progression and recurrence of glioblastoma
Trial sites (1)
Facility
City
Region
Status
CHU de Bordeaux
Bordeaux
France
Recruiting
More University Hospital, Bordeaux trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
